Clinical trial · Interventional
Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.
Phase 2 Study.Tailored Therapy for Hodgkin Lymphoma Based on Predefined Risk Factors and Early Interim PET/CT for Response Assessment and Further Therapy Decisions.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Recently published studies demonstrated very high event free survival for patients with a normal interim PET/CT and a high hazard ratio for progression of an interim positive (pathological)study. These findings strongly support the integration of interim PET as a decision point for adjustment of chemotherapy.This study use the minimal therapy considered safe according to the predefined risk factors for patients with interim negative PET. Those with pathologic interim study considered as higher risk patients will have dose escalation of therapy.remission rate ,event free survival and overall survival will be evaluated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT post 2 cycles of chemotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Early favorable
- description
- patients with early favorable disease Ia IIA will have a PET/CT following 2 cycles of ABVD
- interventionNames
- Other: PET/CT post 2 cycles of chemotherapy
- type
- EXPERIMENTAL
- label
- Early Unfavorable
- description
- Patients with early favorable disease Ia or IIa with risk factors :large mediastinal mass extra nodal disease elevated esr, three or more involved areas, age equal or \>50 , lymphocytic depleted or mixed cellularity
- interventionNames
- Other: PET/CT post 2 cycles of chemotherapy
- type
- EXPERIMENTAL
- label
- advanced disease
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Hodgkin lymphoma patients * age 18-60 for those with early disease and advanced disease with score less then 3 * age 18-60 years for patients with advanced disease score 3 or higher classical Hodgkin lymphoma * WBC more then 3500 * platelets more then 100000 * creatinin less then 2.0 mg * bilirubin less then 2.0 mg * absolute neutrophil count more then 1000 unless bone marrow involvement If marrow involve, patient with lower count but ANC of 1000 may be included. Exclusion Criteria: * Positive serology for HIV * bilirubin more then 2 mg/dl * creatinin more then 2 mg/dl * lactating woman or pregnant * patient older then 60 years with high risk disease of score 3 or more
References
Publications (0)
Data not yet available